Using population-based approaches and biomarker assays on stored samples (in exisiting large biobanks) allows my research to move forward more quickly. I can use these strategies in parallel with my clinical program - to test important questions and to identify candidate assays and targets. In parallel, I develop prospective patient studies for individuals affected with myeloma precursor disease, early intervention studies (MGUS and smoldering myeloma), and targeted myeloma treatment studies. By taking these parallel approaches, and by constantly developing and improving our concepts, I bevieve that we will be able to delay progression and ultimately cure patients from myeloma in the future. Currently, we are developing in vitro models.
The aim of this effort is to develop models to study mechanisms of disease, and to allow us to do drug screening.
|Drahos, Jennifer; Vanwormer, Jeffrey J; Greenlee, Robert T et al. (2013) Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol 23:291-3|
|Shiels, Meredith S; Landgren, Ola; Goedert, James J et al. (2013) Reply to bibas et Al. Clin Infect Dis 56:1350|
|Manasanch, Elisabet E; Kristinsson, Sigurdur Y; Landgren, Ola (2013) Etiology of Waldenstrom macroglobulinemia: genetic factors and immune-related conditions. Clin Lymphoma Myeloma Leuk 13:194-7|
|Kristinsson, Sigurdur Y; Eloranta, Sandra; Dickman, Paul W et al. (2013) Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol 88:60-5|
|Wu, S Peter; Minter, Alex; Costello, Rene et al. (2013) MGUS prevalence in an ethnically Chinese population in Hong Kong. Blood 121:2363-4|